Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults With Major Depressive Disorder (MDD), With or Without Anxious Distress

NCT07065240 is registered in ClinicalTrials.gov with Seaport Therapeutics as lead sponsor.

NCT NCT07065240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07065240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults With Major Depressive Disorder (MDD), With or Without Anxious Distress
Lead sponsor
Seaport Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
June 19, 2025
Completion date
March 31, 2027
Enrollment
360 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd), major depressive disorder with anxious distress